NEW YORK (GenomeWeb News) – Atossa Genetics today said into has signed a nationwide agreement with preferred provider organization HealthSmart.

The agreement, the Seattle-based breast cancer diagnostic firm said, is to provide patients in HealthSmart's network greater access to Atossa's ForeCyte Breast Health Test. The risk stratification test for breast cancer is based on Atossa's US Food and Drug Administration-cleared Mammary Aspirate Specimen Cytology Test System, or MASCT.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.